tbuckley/cabot-search huggingface dataset:
Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: Evidence of Graft-Versus-Lymphoma Effect.
Authors: Mehdi Hamadani, Farrukh Awan, Patrick Elder, Pierluigi Porcu, Thomas Lin, Kristie Blum, Diane Scholl, Steven M. Devine
Journal: Blood (2007)
Increased MSI2 expression Is Associated with Aggressive CML and AML
Authors: Jaspal S Kaeda, Ken I. Mills, Michael G Kharas, Giuseppe Saglio, Michaela Schwarz, Christian Oberender, Bärbel Pawlaczyk-Peter, Antje van Lessen, Seval Türkmen, Claudia D Baldus, Frauke Ringel, Thomas Pretzsch, Peggy Grille, Anna Serra, Anne Carson, Mary Frances McMullin, Jörg Westermann, Peter Daniel, Bernd Dörken, Philipp D. le Coutre
Journal: Blood (2011)
Is Broader Better?
Authors: Elizabeth G. Epstein, Ashley R. Hurst, Dea Mahanes, Mary Faith Marshall, Ann B. Hamric
Journal: The American Journal of Bioethics (2016)

In their article “A Broader Understanding of Moral Distress,” Campbell, Ulrich, and Grady (2016) correctly assert that moral distress is well established in the nursing literature and is gaining at...
Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology
Authors: Roy Altman, Bill Bosch, Kay Brune, Paola Patrignani, Clarence Young
Journal: Drugs (2015)

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. This review illustrates how pharmaceutical technology has been used to modify the pharmacokinetic properties of diclofenac, leading to the creation of novel drug products with improved clinical utility.
Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6
Authors: Atish D. Choudhury, Anna C. Schinzel, Maura B. Cotter, Rosina T. Lis, Katherine Labella, Ying Jie Lock, Francesca Izzo, Isil Guney, Michaela Bowden, Yvonne Y. Li, Jinal Patel, Emily Hartman, Steven A. Carr, Monica Schenone, Jacob D. Jaffe, Philip W. Kantoff, Peter S. Hammerman, William C. Hahn
Journal: Cancer Research (2016)

In prostate cancer, the development of castration resistance is pivotal in progression to aggressive disease. However, understanding of the pathways involved remains incomplete. In this study, we performed a high-throughput genetic screen to identify kinases that enable tumor formation by androgen-dependent prostate epithelial (LHSR-AR) cells under androgen-deprived conditions. In addition to the identification of known mediators of castration resistance, which served to validate the screen, we identified a mitotic-related serine/threonine kinase, NEK6, as a mediator of androgen-independent tumor growth. NEK6 was overexpressed in a subset of human prostate cancers. Silencing NEK6 in castration-resistant cancer cells was sufficient to restore sensitivity to castration in a mouse xenograft model system. Tumors in which castration resistance was conferred by NEK6 were predominantly squamous in histology with no evidence of AR signaling. Gene expression profiling suggested that NEK6 overexpression stimulated cytoskeletal, differentiation, and immune signaling pathways and maintained gene expression patterns normally decreased by castration. Phosphoproteome profiling revealed the transcription factor FOXJ2 as a novel NEK6 substrate, with FOXJ2 phosphorylation associated with increased expression of newly identified NEK6 transcriptional targets. Overall, our studies establish NEK6 signaling as a central mechanism mediating castration-resistant prostate cancer. Cancer Res; 77(3); 753-65. ©2016 AACR.
Testosterone treatment and risk of venous thromboembolism: population based case-control study
Authors: Carlos Martinez, Samy Suissa, Stephan Rietbrock, Anja Katholing, Ben Freedman, Alexander T Cohen, David J Handelsman
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To determine the risk of venous thromboembolism associated with use of testosterone treatment in men, focusing particularly on the timing of the risk. <b>Design</b>&nbsp;Population based case-control study <b>Setting</b>&nbsp;370 general practices in UK primary care with linked hospital discharge diagnoses and in-hospital procedures and information on all cause mortality. <b>Participants</b>&nbsp;19 215 patients with confirmed venous thromboembolism (comprising deep venous thrombosis and pulmonary embolism) and 909 530 age matched controls from source population including more than 2.22 million men between January 2001 and May 2013. <b>Exposure of interest</b>&nbsp;Three mutually exclusive testosterone exposure groups were identified: current treatment, recent (but not current) treatment, and no treatment in the previous two years. Current treatment was subdivided into duration of more or less than six months. <b>Main outcome measure</b>&nbsp;Rate ratios of venous thromboembolism in association with current testosterone treatment compared with no treatment were estimated using conditional logistic regression and adjusted for comorbidities and all matching factors. <b>Results</b>&nbsp;The adjusted rate ratio of venous thromboembolism was 1.25 (95% confidence interval 0.94 to 1.66) for current versus no testosterone treatment. In the first six months of testosterone treatment, the rate ratio of venous thromboembolism was 1.63 (1.12 to 2.37), corresponding to 10.0 (1.9 to 21.6) additional venous thromboembolisms above the base rate of 15.8 per 10 000 person years. The rate ratio after more than six months' treatment was 1.00 (0.68 to 1.47), and after treatment cessation it was 0.68 (0.43 to 1.07). Increased rate ratios within the first six months of treatment were observed in all strata: the rate ratio was 1.52 (0.94 to 2.46) for patients with pathological hypogonadism and 1.88 (1.02 to 3.45) for those without it, and 1.41 (0.82 to 2.41) for those with a known risk factor for venous thromboembolism and 1.91 (1.13 to 3.23) for those without one. <b>Conclusions</b>&nbsp;Starting testosterone treatment was associated with an increased risk of venous thromboembolism, which peaked within six months and declined thereafter.
Von Willebrand Factor/Factor VIII Concentrate (Humate-P®) for Surgical Prophylaxis of Excessive Bleeding in Patients with Von Willebrand Disease (VWD).
Authors: Joan Cox Gill, J. DiPaola, J. Bernstein, C. A. Leissinger, L. Valentino, C. Friedman, S. Knaub
Journal: Blood (2005)
Treatment of Diffuse Large B-Cell Lymphomas
Authors: Aminat U Magomedova, Sergey K Kravchenko, Alexandra Kremenetskaya, Evgenyi Zvonkov, Elena Baryakh, Yana Mangasarova, Irina Kaplanskaya, Rima Samojlova, Ivan A Vorobjev, Tatjana Obuchova, Suren Karagjuljan, Galina Klyasova, Elena Shulutko, Gennadii Galstyan, Dmitrii Marjin, Nelya Gabeeva, Andrey Vorobjev
Journal: Blood (2011)
mTOR Inhibitor Rapamycin Interacts Synergistically with Farnesyltransferase Inhibitor FTI-277 To Induce Growth Inhibition in Human Leukemia Cells.
Authors: June-Won Cheong, Ju In Eom Eom, Hye Won Lee, In-Hae Park, Yuri Kim, Jin Seok Kim, Yoo-Hong Min
Journal: Blood (2007)
Leaps in the dark
Authors: Fiona Godlee
Journal: BMJ (2016)

If your patients need information on fertility treatments, where should they look? Not, it turns out, the websites of the United Kingdom’s in vitro fertilisation (IVF) clinics. There they will find a confusing menu of “add-ons” to standard IVF, with little to support claims that these will increase the chances of a successful pregnancy. As Carl Heneghan and colleagues discovered, most are not backed by evidence of effectiveness, and there is almost no information on harms (doi:10.1136/bmj.i6295). The UK National Institute of Health and Care Excellence and the Cochrane collaboration have made …
NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy
Authors: Alexander JA Deutsch, Beate Rinner, Kerstin Wenzl, Katharina Troppan, Beata Pursche, Hildegard T. Greinix, Christine Beham-Schmid, Peter Neumeister
Journal: Blood (2015)
Abstract 5060: The Effect of Aggressive Dietary Intervention on Endothelial Progenitor Cell Function in High Risk Cardiovascular Patients
Authors: Christine Liao, Mary Keith, Michael A Kuliszewski, Lee Errett, David J Jenkins, Howard Leong-Poi
Journal: Circulation (2008)

Secondary prevention strategies aimed at the reduction of modifiable risk factors can improve outcomes and improve prognosis in high risk cardiovascular patients. Reduced endothelial progenitor cell (EPC) number and functionality, as observed in type II diabetes, reflects increased cardiac risk but nutritional modulation may positively influence endothelial function. Therefore, we hypothesize that an aggressive dietary intervention, the modified Portfolio Diet, would increase the number and/or functionality of EPCs in diabetic patients post-CABG. Methods: 22 patients with type II diabetes, 6 weeks post bypass surgery received detailed individualized dietary counseling on the modified Portfolio Diet: a low cholesterol, low saturated fat diet that includes viscous fibres (8g/1000 kcal as psyllium and β-glucan), soy protein (17g/1000kcal) and almonds (22g/1000kcal). EPCs were isolated by Ficol gradient prior to study entry and at study completion (week 0 vs. week 4) and cultured on fibronectin coated culture...
Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center
Authors: Ellin Berman, Cyrus V. Hedvat, Joseph G. Jurcic, Mark Heaney, Peter G. Maslak, Renier Brentjens, Nicole Lamanna, Todd L. Rosenblat, Mark G. Frattini, Ann A Jakubowski, Suresh Jhanwar
Journal: Blood (2011)
NIMG-50SURVIVAL RATE PREDICTION IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM), USING DYNAMIC CONTRAST ENHANCED MRI AND NESTED MODEL SELECTION TECHNIQUE (NMS)
Authors: Hamed Moradi, Azimeh N.V. Dehkordi, Siamak P. Nejad-Davarani, Reza Faghihi, Brent Griffith, Ali S. Arbab, Tom Mikkelsen, Hamid Soltanian-Zadeh, Lisa Scarpace, Hassan Bagher-Ebadian
Journal: Neuro-Oncology (2015)

Dynamic Contrast Enhanced MRI is being widely used in research and the clinic for grading and evaluation of response to therapy of solid tumors. Prediction of patient survival can play an important role in treatment planning. In this study, using a pharmacokinetic Nested Model-Selection (NMS) technique, 3 different physiological models (1, 2 and 3) were introduced for estimating the following tumor physiological parameters respectively: plasma volume (vp), vp and forward vascular transfer constant (Ktrans), vp, Ktrans and reverse vascular transfer constant (Kep). This pilot study investigates the predictive power of different permeability parameters estimated by the NMS technique for survival of 20 treatment naive patients with GBM. The MR experiments were performed on a 3 Tesla (Signa-Excite, GE) as following: Variable-Flip-Angle (20, 50, 100, 150, 200 and 250, TR = 5.87ms), 3D-SPGRE (flip angle: 300, TR/TE = 5.8/0.84ms, 256 × 256, 5.7 sec temporal time, 16 slices, Magnevist: 0.1mol/kg, 4ml/sec). NMS was used to estimate all the model parameters (vp, Ktrans and Kep). A Cox proportional-hazards regression (CPHR) model (P-value < 0.05, Confidence Level = %95) was used to analyze the survival time of the patients. According to Wald test and p-values estimated by CPHR analysis for all the parameters of the 3 models, only parameters of model 3 (Ktrans, Kep and Ve with p-value of 0.02, 0.027 and 0.025 and Wald test values of 5.4, 4.8 and 5 respectively) provided the best predictors of survival time among the other parameters. The results show an inverse relationship between Kep and survival, while a direct relationship between Ktrans and Ve with survival (i.e., patients with higher values of Ktrans and Ve showed an improved survival) was observed. In conclusion, using NMS technique, this pilot study suggests a possible association between survival and Ktrans, Kep, Ve in GBM patients that may be of considerable clinical importance.
Plasma Brain Derived Neurotropic Factor and Platelet Derived Growth Factor Levels Are Elevated in Children with Sickle Cell Anemia and Abnormal Transcranial Doppler and/or Stroke
Authors: Hyacinth I Hyacinth, Beatrice E Gee, Tom Adamkiewicz, Robert J. Adams, Abdullah Kutlar, Jonathan K Stiles, Jacqueline M Hibbert
Journal: Blood (2011)
Illegitimate V(D)J Recombination Involving Notch1 and Bcl11b in Precursor T-Cell Lymphoblastic Leukemia/Lymphoma
Authors: Masahiro Onozawa, Hyunkyung Kim, Sheryl M Gough, Yingwei Lin, Yongzhi Cui, Sarah H Beachy, Crystal L Mackall, Peter Aplan
Journal: Blood (2012)
High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy
Authors: Sung-Nan Pei, Ming-Chung Wang, Ming-Chung Ma, Ching-Yuan Kuo, Chien-Hung Chen, Po-Nan Wang
Journal: Blood (2015)
Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.
Authors: Shin Mineishi, John Magenau, Attaphol Pawarode, Timothy Buck, Dawn Jones, Koji Kato, David Frame, Lisa Kujawski, Harry Paul Erba, Yasser Khaled, Edward M. Peres, Oleg I. Krijanovski, Pavan Reddy, Carrie Kitko, Sung Choi, Gregory A. Yanik, Thomas Braun, James L.M. Ferrara, John E. Levine
Journal: Blood (2008)
Supportive angiogenic and osteogenic differentiation of mesenchymal stromal cells and endothelial cells in monolayer and co-cultures
Authors: Florian Böhrnsen, Henning Schliephake
Journal: International Journal of Oral Science (2016)

Sites of implantation with compromised biology may be unable to achieve the required level of angiogenic and osteogenic regeneration. The specific function and contribution of different cell types to the formation of prevascularized, osteogenic networks in co-culture remains unclear. To determine how bone marrow-derived mesenchymal stromal cells (BMSCs) and endothelial cells (ECs) contribute to cellular proangiogenic differentiation, we analysed the differentiation of BMSCs and ECs in standardized monolayer, Transwell and co-cultures. BMSCs were derived from the iliac bone marrow of five patients, characterized and differentiated in standardized monolayers, permeable Transwells and co-cultures with human umbilical vein ECs (HUVECs). The expression levels of CD31, von Willebrand factor, osteonectin (ON) and Runx2 were assessed by quantitative reverse transcriptase polymerase chain reaction. The protein expression of alkaline phosphatase, ON and CD31 was demonstrated via histochemical and immunofluorescence analysis. The results showed that BMSCs and HUVECs were able to retain their lineage-specific osteogenic and angiogenic differentiation in direct and indirect co-cultures. In addition, BMSCs demonstrated a supportive expression of angiogenic function in co-culture, while HUVEC was able to improve the expression of osteogenic marker molecules in BMSCs.
NFAT2 Is a Critical Regulator Of Anergy Induction In CLL
Authors: Melanie Märklin, Jonas S. Heitmann, B. Sc., David Worbs, B. Sc., Alexandra Poljak, B. Sc., Claude Evouna, Hans-Georg Kopp, Lothar Kanz, Anjana Rao, Stefan Wirths, Martin R Müller
Journal: Blood (2013)
Once Daily Ganciclovir (ODG) as Initial Pre-Emptive Therapy (PT) Delayed until Threshold Viral Load ≥10,000 Copies/ml: A Safe and Effective Strategy for Post-Allogeneic Stem Cell Transplant (ASCT) Patients.
Authors: Linda A. Verkruyse, Aarti Oza, Steven M. Devine, Douglas R. Adkins, Hanna Khoury, John F. DiPersio, Ravi Vij
Journal: Blood (2004)
A Novel Mechanism of GLI2 Mediated Regulation of IgM Secretion in Waldenström Macroglobulinemia
Authors: David A. Jackson, Timothy D. Smith, Nansalmaa Amarsaikhan, Ann Vrabel, Ezequiel Tolosa, Luciana L. Almada, Martin E. Fernandez-Zapico, Sherine F. Elsawa
Journal: Blood (2014)
Colorectal Liver Metastases: A Critical Review of State of the Art
Authors: Robert P Jones, Norihiro Kokudo, Gunnar Folprecht, Yoshihiro Mise, Michiaki Unno, Hassan Z Malik, Stephen W Fenwick, Graeme J Poston
Journal: Liver Cancer (2016)

Over 50% of patients with colorectal cancer will develop liver metastases. Only a minority of patients present with technically resectable disease. Around 40% of those undergoing surgical resection are alive five years after their diagnosis compared with less than 1% for those with disseminated disease treated with systemic chemotherapy. Surgical resection remains the only possibility for long-term survival for these patients and great efforts have been made to increase the rates of resection whilst improving long-term outcomes.This review considers current technical and oncological criteria for resection, as well as targeted approaches to stratify underlying tumor biology in order to better predict long-term benefit. The role of neoadjuvant and perioperative systemic chemotherapy is critically reviewed, with suggestions for patient stratification in order to identify those who are likely to derive the greatest benefit. The key role of multidisciplinary assessment and decision making for these complex patients is also discussed.Surgery remains the optimal treatment for colorectal liver metastases (CRLM). Despite the curative intent of surgical resection, the majority of patients develop recurrence. Surgical strategies should therefore be adopted to maximize the potential for repeat resections in the event of recurrence. Although a number of preoperative prognostic markers have been identified, none are absolute contraindications to resection. In order to reduce postoperative recurrence, neo-adjuvant chemotherapy is now the standard of care in a number of countries. The evidence base for this approach is contentious, and the potential benefit of such a strategy is likely to be greatest in patients with high oncological risk disease. Multidisciplinary care is essential to ensure the optimal management of these complex patients. In addition, all patients with CRLM should be discussed with specialist hepatobiliary surgeons.
Low cytokeratin- and low EpCAM-expressing circulating tumor cells in pancreatic cancer.
Authors: Daniel Adams, Susan Tsai, Olga V. Makarova, Peixuan Zhu, Shuhong Li, Platte T. Amstutz, Cha-Mei Tang
Journal: Journal of Clinical Oncology (2013)

11046 Background: To date, detecting circulating tumor cells (CTCs) in the peripheral blood of pancreatic patients using standard immuno-capture techniques has met with limited success. As pancreatic cancer is prone to metastasize at distant sites, and therefore should have high numbers of CTCs, it is possible that immuno-capture methods are not suitable for this disease. Using a microfiltration approach, we show that CTCs are present in the peripheral blood in over 75% of pancreatic cancer patients, and that two distinct subtypes can be identified. Methods: Pancreatic patient samples were provided by Medical College of Wisconsin, Milwaukee, WI. CellSieve microfilters, with precision 7 micron diameter pores distributed in uniform arrays were employed. 7.5 mL of whole blood was diluted in pre-fixation solution and filtered through CellSieve microfilters. CTCs collected by this size exclusion technique were fixed, permeabilized, and stained with DAPI, an antibody cocktail against cytokeratin 8, 18 and 19 (FITC), EpCAM (PE), and CD45 (Cy5). CTCs, defined as cytokeratin positive and CD45 negative, were found in two distinct subtypes. One subtype had the “classic” characteristics of a CTC, with high EpCAM and cytokeratin expression, identifiable cytokeratin filamentation, and a cancer-like nuclear structure. The second subtype is indicative of a CTC undergoing epithelial-mesenchymal transition (EMT), with low or no EpCAM, weak cytokeratin expression, and a smooth oval nuclear structure. Results: The “classic” CTCs were found in ~20% (n=40) of patient samples. The EMT-like CTCs were found in ~75% of the same patient cohort. Neither cell was present in any healthy subjects (n=30). EMT-like CTCs consistently lacked EpCAM expression and commonly presented as multi-cell clusters, or microemboli, in ~40% of the cases. Conclusions: We show that two distinct CTC subtypes circulate in the blood of most pancreatic patients. The low expression of cytokeratin and EpCAM of the EMT-like subtype implies that immuno-capture based CTC isolation methods have limited utility for pancreatic cancer. Further, this subtype provides a useful strategy for tracking pancreatic CTCs over the course of treatment.
The Importance of the Number of Transplanted Cells with Dipeptidyl Peptidase-4 Expression on the Hematopoietic Recovery and Lymphocyte Reconstitution in Patients with Multiple Myeloma after Autologous Hematopoietic Stem-Cell Transplantation
Authors: Anna Kopinska, Malgorzata Krawczyk-Kulis, Joanna Dziaczkowska-Suszek, Katarzyna Bieszczad, Krystyna Jagoda, Slawomira Kyrcz-Krzemien
Journal: Blood (2015)
Herpesviridae Viral Infections Following Rituximab Combined Chemotherapy In Patients with Diffuse Large B Cell Lymphoma
Authors: Ho Sup Lee, Lee Chun Park, Seong Hoon Shin, Byeong Jin Ye, Moo-Kon Song, Sung Yong Oh, Sang Min Lee, Won Sik Lee, Yang Soo Kim
Journal: Blood (2010)
Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.
Authors: Harry P Erba, Margaret O'Donnell, Steven L Allen, Maria R Baer, Bayard L Powell, Richard M Stone, John M Bennett, Ante S Lundberg, Robert L Capizzi, David A Rizzieri
Journal: Blood (2009)
High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma
Authors: Pei-Yu Kuo, Violetta V. Leshchenko, Tobias A. Gellen, Netha Ulahannan, Paul Zumbo, Christopher E. Mason, Wyndham H. Wilson, Adrian Wiestner, K. Stephen Suh, Andre Goy, David T. Yang, Brad S. Kahl, Randy D. Gascoyne, Ari Melnick, Samir Parekh
Journal: Blood (2011)
Establishment of Mouse PMF Model by the Introduction of Constitutive STAT5a Into Purified Hematopoietic Stem Cells.
Authors: Takafumi Shimizu, Akihiko Ito, Akira Nakagawa, Toshinobu Nishimura, Satoshi Yamazaki, Shoichi Iriguchi, Shin Kaneko, Hiromitsu Nakauchi
Journal: Blood (2009)